Literature DB >> 17324522

Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes.

P Szot1, S S White, J L Greenup, J B Leverenz, E R Peskind, M A Raskind.   

Abstract

In Alzheimer's disease (AD) there is a significant loss of locus coeruleus (LC) noradrenergic neurons. However, recent work has shown the surviving noradrenergic neurons to display many compensatory changes, including axonal sprouting to the hippocampus. The prefrontal cortex (PFC) is a forebrain region that is affected in dementia, and receives innervation from the LC noradrenergic neurons. Reduced PFC function can reduce cognition and disrupt behavior. Because the PFC is an important area in AD, we determined if noradrenergic innervation from the LC noradrenergic neurons is maintained and if adrenoreceptors are altered postsynaptically. Presynaptic PFC alpha2-adrenoreceptor (AR) binding site density, as determined by 3H-RX821002, suggests that axons from surviving noradrenergic neurons in the LC are sprouting to the PFC of subjects with dementia. Changes in postsynaptic alpha1-AR in the PFC of subjects with dementia indicate normal to elevated levels of binding sites. Expression of alpha1-AR subtypes (alpha1A- and alpha1D-AR) and alpha2C-AR subtype mRNA in the PFC of subjects with dementia is similar to what was observed in the hippocampus with one exception, the expression of alpha1A-AR mRNA. The expression of the alpha1A-AR mRNA subtype is significantly reduced in specific layers of the PFC in subjects with dementia. The loss of alpha1A-, alpha1D- and alpha2C-AR mRNA subtype expression in the PFC may be attributed to neuronal loss observed in dementia. These changes in postsynaptic AR would suggest a reduced function of the PFC. Consequence of this reduced function of the PFC in dementia is still unknown but it may affect memory and behavior.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324522      PMCID: PMC3399726          DOI: 10.1016/j.neuroscience.2007.01.031

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  70 in total

1.  Neuron-glia signaling via alpha(1) adrenoceptor-mediated Ca(2+) release in Bergmann glial cells in situ.

Authors:  A Kulik; A Haentzsch; M Lückermann; W Reichelt; K Ballanyi
Journal:  J Neurosci       Date:  1999-10-01       Impact factor: 6.167

Review 2.  Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions.

Authors:  Amy F T Arnsten; Bao-Ming Li
Journal:  Biol Psychiatry       Date:  2005-06-01       Impact factor: 13.382

Review 3.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

4.  Effect of pentylenetetrazol on the expression of tyrosine hydroxylase mRNA and norepinephrine and dopamine transporter mRNA.

Authors:  P Szot; S S White; R C Veith
Journal:  Brain Res Mol Brain Res       Date:  1997-02

5.  Hippocampal alpha2a-adrenergic receptors are located predominantly presynaptically but are also found postsynaptically and in selective astrocytes.

Authors:  T A Milner; A Lee; S A Aicher; D L Rosin
Journal:  J Comp Neurol       Date:  1998-06-08       Impact factor: 3.215

6.  Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease.

Authors:  C Ballard; C Holmes; I McKeith; D Neill; J O'Brien; N Cairns; P Lantos; E Perry; P Ince; R Perry
Journal:  Am J Psychiatry       Date:  1999-07       Impact factor: 18.112

7.  Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration.

Authors:  R Elrod; E R Peskind; L DiGiacomo; K I Brodkin; R C Veith; M A Raskind
Journal:  Am J Psychiatry       Date:  1997-01       Impact factor: 18.112

8.  Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies.

Authors:  Patricia Szot; Sylvia S White; J Lynne Greenup; James B Leverenz; Elaine R Peskind; Murray A Raskind
Journal:  J Neurosci       Date:  2006-01-11       Impact factor: 6.167

9.  Alpha1-adrenoreceptor in human hippocampus: binding and receptor subtype mRNA expression.

Authors:  Patricia Szot; Sylvia S White; J Lynne Greenup; James B Leverenz; Elaine R Peskind; Murray A Raskind
Journal:  Brain Res Mol Brain Res       Date:  2005-10-03

Review 10.  Mouse models of Alzheimer's disease: insight into treatment.

Authors:  Dwight C German; Amelia J Eisch
Journal:  Rev Neurosci       Date:  2004       Impact factor: 4.353

View more
  32 in total

1.  Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.

Authors:  B A S Reyes; A F Carvalho; P Szot; D J Kalamarides; Q Wang; L G Kirby; E J Van Bockstaele
Journal:  Exp Neurol       Date:  2017-03-21       Impact factor: 5.330

Review 2.  The Emerging Relationship Between Interstitial Fluid-Cerebrospinal Fluid Exchange, Amyloid-β, and Sleep.

Authors:  Erin L Boespflug; Jeffrey J Iliff
Journal:  Biol Psychiatry       Date:  2017-12-07       Impact factor: 13.382

3.  Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca(2+)]i.

Authors:  Leif Hertz; Ditte Lovatt; Steven A Goldman; Maiken Nedergaard
Journal:  Neurochem Int       Date:  2010-04-07       Impact factor: 3.921

4.  The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease.

Authors:  Sergey Kalinin; Paul E Polak; Shao Xia Lin; Amul J Sakharkar; Subhash C Pandey; Douglas L Feinstein
Journal:  Neurobiol Aging       Date:  2011-06-25       Impact factor: 4.673

5.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

Review 6.  [Delirium in geriatric urology patients].

Authors:  K F Becher
Journal:  Urologe A       Date:  2019-04       Impact factor: 0.639

7.  Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia.

Authors:  Lucy Y Wang; Murray A Raskind; Charles W Wilkinson; Jane B Shofer; Carl Sikkema; Patricia Szot; Joseph F Quinn; Douglas R Galasko; Elaine R Peskind
Journal:  Int J Geriatr Psychiatry       Date:  2018-02-15       Impact factor: 3.485

8.  Task-evoked pupil dilation and BOLD variance as indicators of locus coeruleus dysfunction.

Authors:  Jeremy A Elman; Matthew S Panizzon; Donald J Hagler; Lisa T Eyler; Eric L Granholm; Christine Fennema-Notestine; Michael J Lyons; Linda K McEvoy; Carol E Franz; Anders M Dale; William S Kremen
Journal:  Cortex       Date:  2017-10-07       Impact factor: 4.027

9.  Long-term α1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity.

Authors:  Van A Doze; Robert S Papay; Brianna L Goldenstein; Manveen K Gupta; Katie M Collette; Brian W Nelson; Mariaha J Lyons; Bethany A Davis; Elizabeth J Luger; Sarah G Wood; James R Haselton; Paul C Simpson; Dianne M Perez
Journal:  Mol Pharmacol       Date:  2011-07-26       Impact factor: 4.436

10.  Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.

Authors:  Lucy Y Wang; Jane B Shofer; Kirsten Rohde; Kim L Hart; David J Hoff; Yun H McFall; Murray A Raskind; Elaine R Peskind
Journal:  Am J Geriatr Psychiatry       Date:  2009-09       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.